medi-8968
mAbexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01448850)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-1 receptorINHIBITOR
IL1R1 inhibitor
- Interleukin-1 receptor type 1INHIBITOR
IL1R1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109607 ↗
Also known as
- medi8968
- medi-8968
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01838499 | Phase 2 | May 1, 2013 | AstraZeneca, Covance, ICON, PHT Corporation, University of California, San Diego |
| NCT01448850 | Phase 2 | Nov 1, 2011 | MedImmune |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2013 |
| Covance | For profit | 1 | 0 | 1 | 2013 |
| ICON | For profit | 1 | 0 | 1 | 2013 |
| MedImmune | For profit | 1 | 1 | 1 | 2011 |
| PHT Corporation | For profit | 1 | 0 | 1 | 2013 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2013 |
6 organizations
Page 1 / 1